A Food and Drug Administration official questioned the reliability of
recent study results released by Orexigen Inc. (Nasdaq: OREX) indicating that
its obesity treatment Contrave reduced the risk of heart attacks. The stock price dropped 91 cents to close at $7.10.
FDA official questions Orexigen study
March 06, 2015 at 18:28 PM EST
